Spots Global Cancer Trial Database for ridaforolimus
Every month we try and update this database with for ridaforolimus cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED) | NCT00122343 | Endometrial Can... | ridaforolimus | 18 Years - | Merck Sharp & Dohme LLC | |
| Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015) | NCT00288431 | Cancer Sarcoma | ridaforolimus Doxorubicin | 18 Years - | Merck Sharp & Dohme LLC | |
| Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1) | NCT01010672 | Sarcoma | Ridaforolimus | 13 Years - | Merck Sharp & Dohme LLC | |
| Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009) | NCT00736970 | Breast Cancer Breast Neoplasm... | ridaforolimus trastuzumab | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED) | NCT00086125 | Hematologic Mal... Leukemia Myelodysplastic... Myeloid Metapla... Lymphoma | ridaforolimus | 18 Years - | Merck Sharp & Dohme LLC | |
| Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017) | NCT00110188 | Prostate Cancer | ridaforolimus | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3) | NCT01234857 | Breast Cancer | ridaforolimus +... exemestane ridaforolimus dalotuzumab | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027) | NCT01243762 | Neoplasms Malig... | dalotuzumab MK-0752 ridaforolimus MK-2206 | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED) | NCT00086125 | Hematologic Mal... Leukemia Myelodysplastic... Myeloid Metapla... Lymphoma | ridaforolimus | 18 Years - | Merck Sharp & Dohme LLC | |
| Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED) | NCT00060645 | Tumors Lymphoma Multiple Myelom... | ridaforolimus | 18 Years - | Merck Sharp & Dohme LLC | |
| A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064) | NCT01605396 | Breast Neoplasm... | Ridaforolimus Dalotuzumab Exemestane | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3) | NCT01234857 | Breast Cancer | ridaforolimus +... exemestane ridaforolimus dalotuzumab | 18 Years - | Merck Sharp & Dohme LLC | |
| Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer | NCT00770185 | Endometrial Can... | ridaforolimus gene expression... immunohistochem... laboratory biom... | 18 Years - | Canadian Cancer Trials Group | |
| Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED) | NCT00781846 | Solid Tumor | ridaforolimus bevacizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009) | NCT00736970 | Breast Cancer Breast Neoplasm... | ridaforolimus trastuzumab | 18 Years - | Merck Sharp & Dohme LLC | |
| Effect of Ridaforolimus on the Pharmacokinetics of Midazolam (Study MK-8669-044) | NCT01071304 | Relapsed or Ref... | Midazolam Ridaforolimus | 18 Years - | Merck Sharp & Dohme LLC | |
| AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED) | NCT00122343 | Endometrial Can... | ridaforolimus | 18 Years - | Merck Sharp & Dohme LLC | |
| Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma | NCT01169532 | Lymphoma Unspecified Adu... | ridaforolimus vorinostat biopsy pharmacological... laboratory biom... | 18 Years - | Fox Chase Cancer Center | |
| A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064) | NCT01605396 | Breast Neoplasm... | Ridaforolimus Dalotuzumab Exemestane | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-056) | NCT01431534 | Solid Tumors | Ridaforolimus | 6 Years - 17 Years | Merck Sharp & Dohme LLC | |
| Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED) | NCT00694083 | Neoplasm | Ridaforolimus | 20 Years - | Merck Sharp & Dohme LLC | |
| Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6) | NCT00538239 | Metastatic Soft... Metastatic Bone... | ridaforolimus Placebo | 13 Years - | Merck Sharp & Dohme LLC | |
| Pharmacokinetics of Ridaforolimus (MK-8669) in Chinese Participants (MK-8669-059) | NCT01380184 | Cancer, Advance... | ridaforolimus | 18 Years - 75 Years | Merck Sharp & Dohme LLC | |
| Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1) | NCT01010672 | Sarcoma | Ridaforolimus | 13 Years - | Merck Sharp & Dohme LLC | |
| Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED) | NCT00112372 | Cancer | Ridaforolimus | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED) | NCT00694083 | Neoplasm | Ridaforolimus | 20 Years - | Merck Sharp & Dohme LLC | |
| Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Soft Tissue Sarcoma | NCT01296659 | Soft Tissue Sar... | ridaforolimus | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors (8669-028)(COMPLETED) | NCT00704054 | Solid Tumors | ridaforolimus | 1 Year - 17 Years | Merck Sharp & Dohme LLC | |
| Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6) | NCT00739830 | Endometrial Can... | ridaforolimus medroxyprogeste... chemotherapy | 18 Years - | Merck Sharp & Dohme LLC | |
| Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED) | NCT00060632 | Tumors Lymphoma Multiple Myelom... | ridaforolimus | 18 Years - | Merck Sharp & Dohme LLC | |
| Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6) | NCT00538239 | Metastatic Soft... Metastatic Bone... | ridaforolimus Placebo | 13 Years - | Merck Sharp & Dohme LLC | |
| Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED) | NCT00781846 | Solid Tumor | ridaforolimus bevacizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1) | NCT01431547 | Solid Tumors | dalotuzumab dalotuzumab ridaforolimus | 3 Years - 17 Years | Merck Sharp & Dohme LLC | |
| Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED) | NCT00781846 | Solid Tumor | ridaforolimus bevacizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| Effect of Ridaforolimus on the Pharmacokinetics of Midazolam (Study MK-8669-044) | NCT01071304 | Relapsed or Ref... | Midazolam Ridaforolimus | 18 Years - | Merck Sharp & Dohme LLC | |
| Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer | NCT01212627 | Non-Small Cell ... | Ridaforolimus | 18 Years - | Brown University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
